What did @steventhephysiologist actually say?
The creator covered four peptides in response to a viewer question about whether BPC-157 is the only peptide worth knowing. They described BPC-157 as something that "heals everything," called Thymosin Alpha-1 a "cancer adjunct" used for autoimmune diseases, said Thymosin Beta-4 "regrows blood vessels" after heart attacks and traumatic brain injuries, and characterized Dihexa as a nootropic that "causes neurogenesis and synaptogenesis" by increasing BDNF. They also briefly mentioned MOTS-c as an "exercise mimicry" peptide for mitochondrial dysfunction. The claims ranged from genuinely supported in early research to wildly overstated, sometimes within the same sentence. The language throughout was confident and clinical-sounding, which matters when 15,000 people are listening.
Does the science back this up?
Some of it, partially. Thymosin Alpha-1 has the strongest evidence base here, but "cancer adjunct" and autoimmune treatment are still largely investigational. Dihexa's neurogenesis claims are real but almost entirely from animal studies. The rest ranges from plausible-but-overstated to just wrong.
Thymosin Alpha-1 (Ta1) has been studied as an immune modulator since the 1970s. It is approved in some countries for hepatitis B and C and has been studied as an adjunct in cancer immunotherapy. Tuthill et al. (2014, Expert Opinion on Biological Therapy) noted its immunostimulatory effects, not immunosuppression, which directly contradicts the creator's claim that it "turns off your immune system from attacking itself." That framing describes immunosuppression; Ta1 is actually an immunopotentiator.
Thymosin Beta-4 (TB-500) has shown angiogenic activity in preclinical models. Philp et al. (2004, Journal of Cell Science) documented its role in actin sequestration and wound repair. Heart attack and TBI applications remain speculative and have not reached clinical validation in humans.
Dihexa's BDNF-related mechanisms come from McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics), showing cognitive improvements in aged rats. No human clinical trials have been completed.
What did they get wrong (or right)?
The biggest factual error is the claim that Thymosin Alpha-1 "turns off your immune system from attacking itself." This is backwards. Ta1 is an immune stimulant, not a suppressant. It enhances T-cell function. Using it to frame autoimmune relief through immune suppression is a fundamental mechanistic error that could mislead people with conditions like MS or rheumatoid arthritis into expecting the wrong pharmacological effect.
Saying BPC-157 "heals everything" is not a claim, it is a liability. No peptide heals everything. BPC-157 has shown interesting results in rat models of gut injury and tendon repair (Sikiric et al., 2018, Current Pharmaceutical Design), but human trial data remains limited and it is not FDA-approved for any indication.
What the creator got broadly right: MOTS-c does have mitochondrial-related mechanisms (Lee et al., 2015, Cell Metabolism). Dihexa does appear to modulate BDNF-related pathways in animal models. Thymosin Beta-4 does have angiogenic properties in preclinical research. These are real areas of scientific interest. The problem is the jump from "studied in rats" to "take it after a heart attack," which is not a small leap.
What should you actually know?
None of these peptides are FDA-approved treatments for the conditions mentioned. If you hear someone listing peptides alongside Lyme disease, MS, TBI, and heart attacks without mentioning that the evidence base is almost entirely preclinical or early-phase, that is a red flag worth noting.
Thymosin Alpha-1 is the most clinically studied of the group and has the most legitimate use cases, particularly in immune support contexts under physician supervision. The others are in earlier stages of human research. Dihexa in particular has no completed human safety trials, which makes confident nootropic claims premature.
The creator uses terms like "neurogenesis" and "synaptogenesis" correctly in the Dihexa section, and the BDNF connection is real. That is the most accurate segment of the video, ironically about the peptide with the least human data. If you are curious about any of these compounds, the conversation starts with a qualified provider who can assess your individual health context, not a TikTok comment section.